Covered recipient · General Payments record
ILDEFONSO I RODRIGUEZ RIVERA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,398.92
54 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,323.93 | 53 |
| Education | $74.99 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BeiGene USA, Inc. | $140.76 | 1 |
| Janssen Biotech, Inc. | $135.97 | 6 |
| Lilly USA, LLC | $105.52 | 4 |
| E.R. Squibb & Sons, L.L.C. | $93.39 | 4 |
| Daiichi Sankyo Inc. | $80.18 | 4 |
| Inspire Medical Systems, Inc. | $76.98 | 2 |
| Astellas Pharma US Inc | $74.99 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $68.95 | 3 |
| Deciphera Pharmaceuticals Inc. | $65.59 | 2 |
| PFIZER INC. | $63.87 | 3 |
| Novartis Pharmaceuticals Corporation | $53.91 | 2 |
| ARRAY BIOPHARMA INC | $52.67 | 3 |
| Merck Sharp & Dohme LLC | $50.48 | 3 |
| ABBVIE INC. | $46.83 | 2 |
| SpringWorks Therapeutics, Inc. | $43.78 | 2 |
| Sumitomo Pharma America, Inc. | $39.56 | 2 |
| SOBI, INC | $34.08 | 1 |
| AstraZeneca Pharmaceuticals LP | $31.24 | 1 |
| TAIHO ONCOLOGY, INC. | $24.29 | 1 |
| Exelixis Inc. | $21.48 | 1 |
| TerSera Therapeutics LLC | $18.35 | 1 |
| Ipsen Biopharmaceuticals, Inc | $17.98 | 1 |
| Blueprint Medicines Corporation | $15.46 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.09 | 1 |
| GENZYME CORPORATION | $14.37 | 1 |
| Menarini Silicon Biosystems, Inc. | $13.15 | 1 |
Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ILDEFONSO I RODRIGUEZ RIVERA
NPI 1861783185 · CMS profile ID 473649
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAN ANTONIO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ILDEFONSO I RODRIGUEZ RIVERA, NPI 1861783185, CMS profile ID 473649. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ILDEFONSO I RODRIGUEZ RIVERA, NPI 1861783185, CMS profile ID 473649. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ILDEFONSO I RODRIGUEZ RIVERA, NPI 1861783185, CMS profile ID 473649, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861783185?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
54 matching records · $1,398.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–54 of 54.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $24.02 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078756131 | CMS |
| Lilly USA, LLC | $19.07 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135033564 | CMS |
| Novartis Pharmaceuticals Corporation | $24.47 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087175945 | CMS |
| GENZYME CORPORATION | $14.37 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139913055 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $248.88 | 1 |
| PY2025 | Principal investigator | $1,323,437.22 | 105 |
| PY2024 | Recipient | $53.84 | 1 |
| PY2024 | Principal investigator | $1,256,038.97 | 117 |
| PY2023 | Principal investigator | $116,817.17 | 13 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
106 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 12/30/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235977717 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $15,856.00 | 12/19/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235977131 |
| Principal investigator 1 | PFIZER INC. | $2,298.51 | 12/16/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228737989 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $122.00 | 12/15/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330799 |
| Principal investigator 1 | BeOne Medicines Ltd. | $12,973.25 | 12/09/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335695 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,375.00 | 12/09/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190329371 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $9,661.00 | 12/09/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190329373 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $248.88 | 12/09/2025 | Covered Recipient Physician | A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES | No dispute reported | 06/30/2026 | 1184121825 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 12/02/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235976852 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,544.00 | 11/28/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335687 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,772.00 | 11/28/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335700 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $10,528.00 | 11/28/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327173 |
| Principal investigator 1 | PFIZER INC. | $4,631.31 | 11/26/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228730639 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $42,112.00 | 11/21/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235976283 |
| Principal investigator 1 | BeOne Medicines Ltd. | $6,000.00 | 11/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335683 |
| Principal investigator 1 | BeOne Medicines Ltd. | $297.00 | 11/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335690 |
| Principal investigator 1 | BeOne Medicines Ltd. | $150.00 | 11/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335704 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,475.85 | 11/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335708 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,005.00 | 11/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190335714 |
| Principal investigator 1 | PFIZER INC. | $9,795.33 | 11/14/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228738113 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $3,000.00 | 11/12/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235976009 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $5,000.00 | 11/12/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235976013 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $24,750.00 | 11/12/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235976017 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $255,600.00 | 11/12/2025 | Non-covered Recipient Entity Next Oncology | A Multicenter Phase I,Ib Dose Escalation Study of WTX 124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232932543 |
| Principal investigator 1 | PFIZER INC. | $12,806.94 | 11/04/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228728483 |
| Principal investigator 1 | PFIZER INC. | $29,750.00 | 11/04/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | A PHASE 1 OPENLABEL STUDY TO INVESTIGATE PF08046876 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228738337 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $50,908.00 | 10/28/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327193 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,483.00 | 10/28/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190329375 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $5,725.00 | 10/22/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235975595 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $5,040.00 | 10/22/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235975619 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 10/18/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235975534 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $450.00 | 10/18/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235975537 |
| Principal investigator 1 | PFIZER INC. | $20,899.77 | 10/08/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228742030 |
| Principal investigator 1 | Amgen Inc. | $113,951.00 | 10/07/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1246645060 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 10/07/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235975028 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $26,142.00 | 09/30/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327203 |
| Principal investigator 1 | BeOne Medicines Ltd. | $395.00 | 09/23/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190340932 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $61.00 | 09/15/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330815 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 09/09/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235974196 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $9,234.00 | 09/02/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327201 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $161.37 | 08/31/2025 | Non-covered Recipient Entity Next Oncology | A Phase 1 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-4700 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232929235 |
| Principal investigator 1 | BeOne Medicines Ltd. | $790.00 | 08/26/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190340942 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $315.00 | 08/15/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235973797 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $75.00 | 08/15/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | No dispute reported | 06/30/2026 | 1235973800 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 08/12/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235973626 |
| Principal investigator 1 | BeOne Medicines Ltd. | $300.00 | 07/22/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190330821 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,475.00 | 07/22/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190330823 |
| Principal investigator 1 | BeOne Medicines Ltd. | $395.00 | 07/22/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190340936 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $12,915.00 | 07/22/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327199 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $30,384.00 | 07/15/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327181 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 07/15/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330813 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 07/15/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235972992 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $5,290.19 | 07/07/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330811 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,976.40 | 06/24/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326724 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,607.00 | 06/24/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330807 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $183.00 | 06/24/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330809 |
| Principal investigator 1 | Amgen Inc. | $9,932.12 | 06/23/2025 | Non-covered Recipient Entity NEXT ONCOLOGY | A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1246645307 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $6,870.00 | 06/19/2025 | Non-covered Recipient Entity NEXT EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235972571 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 06/19/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235972575 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,158.00 | 06/17/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190331097 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $17,916.00 | 06/17/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190331179 |
| Principal investigator 1 | PFIZER INC. | $7,719.30 | 06/14/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07329640 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228774738 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,244.00 | 06/10/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326762 |
| Principal investigator 1 | Amgen Inc. | $5,081.58 | 06/04/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1246645072 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,939.38 | 06/03/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326760 |
| Principal investigator 1 | BeOne Medicines Ltd. | $300.00 | 05/30/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326758 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,772.00 | 05/30/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326764 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,500.00 | 05/30/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326722 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $27,200.00 | 05/30/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327179 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $244.00 | 05/30/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330805 |
| Principal investigator 1 | BeiGene, Ltd. | $35,540.00 | 05/20/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321248 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $9,151.00 | 05/13/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190331177 |
| Principal investigator 1 | BeiGene, Ltd. | $3,500.00 | 05/05/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321256 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,287.00 | 05/02/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES | No dispute reported | 06/30/2026 | 1184191967 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,896.68 | 04/29/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326726 |
| Principal investigator 1 | PFIZER INC. | $31,000.00 | 04/22/2025 | Non-covered Recipient Entity New Experimental Therapeutics of San Antonio LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046032 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228795993 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $47,414.00 | 04/17/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327177 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $305.00 | 04/17/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190330803 |
| Principal investigator 1 | BeiGene, Ltd. | $88,651.00 | 04/17/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321246 |
| Principal investigator 1 | BeiGene, Ltd. | $1,270.00 | 04/17/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321258 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $6,870.00 | 04/09/2025 | Non-covered Recipient Entity NEXT EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235971432 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,890.00 | 04/09/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235971440 |
| Principal investigator 1 | BeiGene, Ltd. | $635.00 | 04/01/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321254 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,000.00 | 03/24/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190330903 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $18,083.00 | 03/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190326208 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $40,200.00 | 03/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190327175 |
| Principal investigator 1 | BeiGene USA, Inc. | $853.47 | 03/11/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321240 |
| Principal investigator 1 | BeiGene, Ltd. | $400.00 | 03/11/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190322582 |
| Principal investigator 1 | BeiGene, Ltd. | $1,558.94 | 03/11/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190322584 |
| Principal investigator 1 | BeiGene, Ltd. | $300.00 | 03/11/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190323380 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $4,410.00 | 03/04/2025 | Non-covered Recipient Entity NEXT EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235970778 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $4,410.00 | 03/04/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | No dispute reported | 06/30/2026 | 1235970807 |
| Principal investigator 1 | BeiGene USA, Inc. | $30,241.00 | 02/25/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190323426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,000.00 | 02/25/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES | No dispute reported | 06/30/2026 | 1184155482 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $775.00 | 02/25/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES | No dispute reported | 06/30/2026 | 1184155484 |
| Principal investigator 1 | BeiGene, Ltd. | $21,786.00 | 02/20/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321242 |
| Principal investigator 1 | BeiGene USA, Inc. | $20,750.00 | 02/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321252 |
| Principal investigator 1 | BeiGene, Ltd. | $305.00 | 02/18/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190325554 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $24,750.00 | 02/13/2025 | Non-covered Recipient Entity NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC | A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES | No dispute reported | 06/30/2026 | 1184153932 |
| Principal investigator 1 | BeiGene USA, Inc. | $635.00 | 02/04/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190325558 |
| Principal investigator 1 | BeiGene, Ltd. | $61.00 | 01/28/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190325556 |
| Principal investigator 1 | BeiGene USA, Inc. | $13,845.00 | 01/21/2025 | Non-covered Recipient Entity NEXT Oncology | A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321250 |
| Principal investigator 1 | BeiGene, Ltd. | $7,868.00 | 01/21/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190321244 |
| Principal investigator 1 | BeiGene, Ltd. | $1,500.00 | 01/21/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190323376 |
| Principal investigator 1 | BeiGene, Ltd. | $4,479.18 | 01/21/2025 | Non-covered Recipient Entity NEXT Oncology | A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1190323378 |
| Principal investigator 1 | Amgen Inc. | $4,861.65 | 01/09/2025 | Non-covered Recipient Entity NEXT ONCOLOGY | Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1246645320 |